Home » Healthcare » Conjugate Vaccines Market

Conjugate Vaccines Market By Target Pathogen (Aviation Gasoline (Avgas), Jet Fuel (Jet-A and Jet-A1)) By Age Group (Commercial Aviation, Military Aviation, General Aviation)-Growth, Future Prospects & Competitive Analysis, 2022 – 2030

Summary
Table Of Content

Market Insights

The global demand for Conjugate Vaccines was valued at USD 18154.5 Million in 2022 and is expected to reach USD 38915.7 Million in 2030, growing at a CAGR of 10.00% between 2023 and
Pneumococcal Vaccines is the fastest growing segment, while Meningococcal Vaccines is another significant category in the Conjugate Vaccines market.
Pediatrics will grow the most, and the adult market will grow as well, but children will grow at the fastest rate.
The DTP (diphtheria-tetanus-pertussis) category outperformed all others, and the pneumococcal category is expected to grow at the fastest pace over the projection period.
Multivalent Conjugate Vaccines have the largest market share, with Monovalent being the second most important group.
The Private Sector is the fastest expanding market segment, followed by the Public Sector.
The Preventive Vaccines sector has the biggest market demand, followed by Travel Vaccines.
The Pediatric Population drives market demand, and High-Risk Populations are another important market sector.
Brand-Specific Vaccines has a substantial market share.
North America would account for 35% of the total market in 2022, with Asia Pacific being the fastest-growing region.

Improving healthcare infrastructure and growing R&D investment are expected to drive market growth.
Side effects from vaccines and licensing delays are projected to limit market expansion.

Executive Summary

Market Definition

The Conjugation Vaccines Market is the market for vaccinations created with conjugation technology. Conjugate vaccines are a form of vaccination that combines a weak antigen with a carrier protein to boost immunity and offer long-term immunity. These vaccinations are often used to prevent bacterial illnesses such meningitis, pneumonia, and Haemophilus influenzae type b (Hib). The Conjugate vaccinations Market encompasses the manufacture, distribution, and sale of these vaccinations, which play an important role in the prevention of infectious illnesses and the promotion of public health.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Overview

It is anticipated that between 2023 and 2030, the worldwide Conjugate Vaccines Market will expand at a compound annual growth rate (CAGR) of 10.00%. From USD 18154.5 million in 2022, the market is projected to be worth USD 38915.7 million by 2030.

Pneumococcal disease refers to a group of conditions that are caused by an infection with the bacteria Streptococcus pneumoniae, often known as pneumococcus. Pneumococcal illness is most common in young children under the age of five, older persons over the age of 65, and people with compromised immune systems. Streptococcus pneumoniae (pneumococcus) can cause pneumonia, sinusitis, meningitis, osteomyelitis, bacteremia, and septic arthritis, among other things. Vaccines aid in the prevention of invasive pneumococcal illnesses. Pneumococcal illnesses are common in South Asian and Sub-Saharan African nations.

Vaccines to combat many types of bacterial illnesses, particularly pneumonia, are in high demand in these countries. In light of this, several top vaccine producers are engaging in vaccine research and development. Because pneumonia is prevalent in many countries, the demand for PCV vaccinations is increasing. 147 nations have included PCV in their National Immunization Program as of March 2021. This is likely to increase demand for OCV vaccinations. In countries where pneumococcal illnesses are common, the government is launching steps to combat the disease.

Segmentation by Target Pathogen

Pneumococcal Vaccines is the fastest-growing sector. Because of their usefulness in preventing pneumococcal illnesses such as pneumonia, meningitis, and bloodstream infections, these vaccines have experienced substantial advances and rising demand.
Meningococcal Vaccines are another major category in the Conjugate Vaccines market.

Segmentation by Age Group

Pediatrics will expand the most since infants and children are more susceptible to most diseases, requiring treatment sooner and being affected by the infection.
The adult market will also accelerate, but children will have the highest CAGR.

Segmentation by Carrier Protein

The DTP (diphtheria-tetanus-pertussis) section dominated all others. The increase in the amount of respiratory tract infections, as well as their contagious nature, is to blame for the spread of DTP.
In addition, the pneumococcal category is predicted to expand at the quickest rate during the projection period.

Segmentation by Valency

Multivalent Conjugate Vaccines have the biggest market share and are expected to expand at the fastest CAGR during the forecast period. The multivalent conjugate vaccination contains two or more antigen strains or serotypes.
Monovalent is the second most important segment in the market.

Segmentation by Distribution Channel

The Private Sector is the fastest growing segment. Vaccine research and development, production, and distribution are becoming increasingly important to the private sector. This expansion can be due to rising vaccine demand, technological breakthroughs, and a greater emphasis on preventive healthcare.
The Public Sector is another prominent market area. The public sector is critical in vaccine distribution, particularly in giving vaccines to underprivileged people, developing immunization programs, and assuring universal access to vaccines.

Segmentation by Application

The Preventive Vaccines sector has the highest market demand. Preventive vaccinations are in high demand because they help protect people from infectious diseases such as measles, mumps, rubella, hepatitis, and influenza.
Travel Vaccines are another major market area. These vaccines are specifically designed to defend against diseases that are widespread in various parts of the world.

Segmentation by Patient Population

The Pediatric Population is the segment that drives market demand. Vaccinations are critical in protecting children from a variety of diseases, and vaccine demand in the pediatric population is constantly high.
High-Risk Populations are another key market category.

Segmentation by Brand

The Brand-Specific Vaccines segment has a sizable market share. Brand-specific vaccinations are those that are developed and marketed under the brand names of individual pharmaceutical companies. These vaccines may have novel formulations, delivery mechanisms, or be designed to target specific diseases.

Segmentation by Region

North America held the largest share with 35% of the overall market in 2022
During the forecasted period of 20222-2027, Asia Pacific would be the fastest-growing segment.
The rest of the world, including Latin America, the Middle East, and Africa, supplies the remaining demand for Conjugate Vaccines.

North America held the greatest market share and is expected to grow at an 8.52% CAGR during the projection period. This region is made up of developed countries that provide comprehensive healthcare systems, research, and development, and are thus regarded as the well-developed public healthcare region. Because of the existence of established important companies in the region with healthcare infrastructure, the North American region is expected to dominate the overall market.

However, Asia-Pacific is expected to be the fastest-growing market between 2022 and 2027. This increase is due to a growing population gravitating toward communicable diseases on a large scale, increasing government and private sector investments in research and development of new procedures and vaccines, and refining healthcare infrastructure in various developing Asian nations such as India, Indonesia, and China.

Key Highlights of the Report

The global Conjugate Vaccines Market is segmented by Target Pathogen, Age Group, Carrier Protein, Valency, Distribution Channel, Application, Patient Population, Brand, Price Range and region. The most common type of vaccine is a multivalent conjugate vaccine. In addition, the fastest increasing category is the private sector and pneumococcal vaccines. Also, the Preventive Vaccines sector has the biggest market demand, with the Brand-Specific Vaccines segment accounting for a sizable market share, with North Amerca leading the market growth.

Increasing awareness and importance of vaccination against bacterial infections, Advancements in vaccine technology, leading to improved efficacy and safety and Growing government initiatives and immunization programs to prevent infectious diseases are the key drivers of the market. Moreover, High costs associated with the development and production of conjugate vaccines, Stringent regulatory requirements for vaccine approval and market entry and Limited accessibility and affordability of vaccines in certain regions are the restraint in the market

Nonetheless, North America held the largest market share and is predicted to increase at an 8.52% CAGR over the forecast period. This region is made up of developed countries that provide extensive healthcare systems, research, and development, and are consequently recognized as the region with the most developed public healthcare. However, between 2022 and 2027, Asia-Pacific is predicted to be the fastest-growing market.

What Elements Are Driving the Global Market for Conjugate Vaccines?

Individuals are becoming more aware of the importance of vaccination in protecting against bacterial diseases. This increased awareness has resulted in a greater demand for combination vaccinations. Furthermore, advances in vaccination technology have greatly enhanced the efficiency and safety of these immunizations. This has increased trust in their effectiveness, propelling the market forward.

What Are The Main Obstacles That The Global Conjugate Vaccines Market Faces?

The high costs associated with the research and production of conjugate vaccines are a substantial impediment. Because research, clinical trials, and manufacturing processes can be costly, it can be difficult for some companies to enter the market or supply affordable vaccinations. Furthermore, strict regulatory criteria for vaccination approval and market access might be a barrier to new entrants. These rules safeguard vaccine safety and efficacy, but they can also hinder the launch of new medications.

What Market Development Prospects Are There For Conjugate Vaccines Globally?

With developing healthcare infrastructure in emerging markets, there is a considerable possibility for expansion. As these countries’ healthcare systems develop, there is a larger chance of increasing vaccination acceptance and market growth. Furthermore, the development of conjugate vaccines for new target diseases and age ranges opens up new business opportunities. Companies can enter new markets and reach a larger population by solving unmet medical needs.

Market Drivers

The global Conjugate Vaccines Market is driven by several factors. The following are the key drivers of the global Conjugate Vaccines Market:

Improving Healthcare Infrastructure And Increasing R&D Funding

Following the Covid outbreak, there has been a worldwide surge in numerous transmissible diseases. As a result, the healthcare sector is at the top of the government’s priority list. Developing countries are putting together massive packages for R&D and increasing their overall healthcare spending. Recently, the Indian government increased healthcare spending by 137%. Even in the United States, total healthcare spending is expected to exceed $6 trillion by 2028-2029. As a result of growing flows of hard cash, medication and vaccine development activities are increasing around the world, which is expected to enhance the Meningococcal Conjugate Vaccine Market.

Market Restraints

The global Conjugate Vaccines Market faces some challenges that may hinder its growth. These include the following:

Vaccine Side Effects And Licensing Delays

Vaccines are not completely safe and have numerous negative effects after use. Similarly, in many circumstances, meningococcal conjugate vaccinations such as MenACWY and MenB comprise several health coercions. Almost complete loss of palate, discomfort, headache, and sleep strain are common in people who have received corresponding immunizations. Furthermore, international health organizations such as WHO and individual governments of countries take an eternity to approve vaccines, which can stymie the development of the meningococcal conjugate vaccine industry.

Opportunities

The global Conjugate Vaccines Market offers significant growth opportunities. These include the following:

Development of Conjugate Vaccines For New Target Diseases And Age Groups

We may precisely target diseases that may not have had effective preventive measures in the past by developing these vaccinations. For instance, Conjugate vaccines have been effective in preventing diseases such as meningitis, pneumonia, and Haemophilus influenzae type b (Hib) infections. By extending the use of conjugate vaccines to new target diseases, we may be able to prevent a broader spectrum of illnesses and problems.

In addition, producing conjugate vaccines for various age groups enables us to address individual vaccination needs at various periods of life. Vaccines designed specifically for older persons, for example, can help protect against diseases such as shingles and pneumococcal infections.

Competitive Landscape

Key Players

The global Conjugate Vaccines Market is highly competitive, with several key players. Some of the major players in the market and their market share are as follows:

Sanofi S.A
Pfizer, Inc.
Merck & Co., Inc.
GlaxoSmithKline plc.
Bharat Biotech, Serum institute of India Pvt. Ltd.
Biological E. Limited
Bio-Med
Bavarian Nordic
CSL Limited
Novartis AG
Vaxcyte
GSBPL
Taj Pharmaceuticals Limited
Bavarian Nordic.

These organizations prioritize Target Pathogen innovation, Disease Area expansion, and mergers and acquisitions to stay competitive.

The global Conjugate Vaccines Market’s key players continually seek to stay ahead by offering new Target Pathogens and developments.

In 2022, Pfizer Inc., a pharmaceutical and biotechnology firm headquartered in the United States, has introduced Prevnar 20, a pneumococcal 20-valent conjugate vaccination, in Canada to prevent pneumonia and invasive pneumococcal infections in individuals aged 18 and older. Prevnar 20 contains conjugates for the 13 serotypes previously covered by PREVNAR 13, as well as conjugates for seven additional serotypes linked to invasive pneumococcal illness, high case fatality rates, antibiotic resistance, and meningitis.

In August 2022, GSK, a pharmaceutical and biotechnology corporation based in the United Kingdom, paid $2.1 billion for Affinivax Inc. GSK intends to use this acquisition to establish a strong portfolio of specialist medicines and vaccines, as well as to expand its position in advanced pneumococcal vaccines, such as AFX3772. Affinivax is a biotechnology business established in the United States that specializes in the development of conjugate vaccines.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Summary of Key Findings

Side effects from vaccines and licensing delays are projected to limit market expansion.

Market segmented by Target Pathogen, Age Group, Carrier Protein, Valency, Distribution Channel, Application, Patient Population, Brand, and region.
Brand-Specific Vaccines has a substantial market share.
Multivalent Conjugate Vaccines have the largest market share
North America is leading market growth; the market is highly competitive with key players including Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech

Future Outlook

There is a growing demand for effective bacterial infection vaccine.
Increasing spending in novel combination vaccine research and development.
Expansion of immunization programs in developing countries.
Advances in vaccine manufacture and delivery technology.
Increasing public knowledge of the necessity of immunization.
Pharmaceutical company collaborations and alliances.
Government initiatives to promote illness prevention and immunization.

Segmentation

By Target Pathogen:

Aviation Gasoline (Avgas)
Jet Fuel (Jet-A and Jet-A1)

By Age Group:

Commercial Aviation
Military Aviation
General Aviation

By Carrier Protein:

Commercial Aircraft
Military Aircraft
General Aviation Aircraft
Valency:
Jet-A
Jet-A1
Avgas 100LL

By Distribution Channel:

Additive-Free
With Anti-Icing Distribution Channel
With Fuel System Icing Inhibitors (FSII)

By Application:

Aerodrome Fuel Suppliers
Conjugate Vaccines Trucking Services
Conjugate Vaccines Pipelines

By Regulation and Standards:

Federally Regulated
International Standards (e.g., ASTM)

By Brand:

Conventional Conjugate Vaccines
Sustainable Conjugate Vaccines

By Price Range:

Standard Conjugate Vaccines
Premium Conjugate Vaccines

By Region

North America
- U.S
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa

Adjacent Markets

In the Conjugate Vaccines Market, there are several adjacent markets which has high revenue growth opportunities. The key adjacent markets for Conjugate Vaccines Market-

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Market Introduction

2. Executive Summary
2.1. Market Snapshot: Global Conjugate Vaccines Market
2.1.1. Global Conjugate Vaccines Market, By Target Pathogen
2.1.2. Global Conjugate Vaccines Market, By Age Group
2.1.3. Global Conjugate Vaccines Market, By Carrier Protein
2.1.4. Global Conjugate Vaccines Market, By Valency
2.1.5. Global Conjugate Vaccines Market, By Distribution Channel
2.1.6. Global Conjugate Vaccines Market, By Application
2.1.7. Global Conjugate Vaccines Market, By Patient Population
2.1.8. Global Conjugate Vaccines Market, By Brand
2.1.9. Global Conjugate Vaccines Market, By Region
2.2. Insights from Primary Respondents

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Conjugate Vaccines Market Value, 2017-2030, (US$ Mn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Conjugate VaccinesMarket Drivers
3.2.2. Conjugate VaccinesMarket Restraints
3.2.3. Conjugate VaccinesMarket Opportunities
3.2.4. MajorConjugate Vaccines Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Target Pathogen
3.5.2. Age Group
3.5.3. Carrier Protein
3.5.4. Valency
3.5.5. Distribution Channel
3.5.6. Application
3.5.7. Patient Population
3.5.8. Brand
3.5.9. Geography

4. Market Competitive Landscape Analysis
4.1. Company Market Share Analysis, 2022
4.1.1. Global Conjugate Vaccines Market: Company Market Share, Value 2022
4.1.2. Global Conjugate Vaccines Market: Top 6 Company Market Share, Value 2022
4.1.3. Global Conjugate Vaccines Market: Top 3 Company Market Share, Value 2022
4.2. Global Conjugate Vaccines Market: Company Revenue Share Analysis, 2022
4.3. Company Assessment Metrics, 2022
4.3.1. Stars
4.3.2. Emerging Leaders
4.3.3. Pervasive Players
4.3.4. Participants
4.4. Startups/ SMEs Assessment Metrics, 2022
4.4.1. Progressive Companies
4.4.2. Responsive Companies
4.4.3. Dynamic Companies
4.4.4. Starting Blocks
4.5. Strategic Development
4.5.1. Acquisition and Mergers
4.5.2. New Product Launch
4.5.3. Regional Expansion
4.5.4. Partnerships
4.6. Key Player Product Matrix
4.7. Potential for New Players in the Global Conjugate Vaccines Market

5. Premium Insights
5.1. STAR (Situation, Task, Action, Results) Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Bargaining Power of Buyers/Consumers
5.2.3. Bargaining Power of Suppliers
5.2.4. Threat of Substitute Types
5.2.5. Intensity of Competitive Rivalry
5.3. PESTEL Analysis
5.3.1. Political Factors
5.3.2. Economic Factors
5.3.3. Social Factors
5.3.4. Technological Factors
5.3.5. Environmental Factors
5.3.6. Legal Factors
5.4. Key Market Trends
5.4.1. Demand Side Trends
5.4.2. Supply Side Trends
5.5. Value Chain Analysis
5.6. Technology Analysis
5.6.1. Research and development in the global market
5.6.2. Patent Analysis
5.6.3. Emerging technologies and their potential disruption to the market
5.7. Consumer Behaviour Analysis
5.7.1. Consumer Preferences and Expectations
5.7.2. Factors Influencing Consumer Buying Decisions
5.7.2.1. North America
5.7.2.2. Europe
5.7.2.3. Asia Pacific
5.7.2.4. Latin America
5.7.2.5. Middle East and Africa
5.7.3. Consumer Pain Points
5.8. Analysis and Recommendations
5.9. Adjacent Market Analysis

6. Market Positioning of Key Players, 2022
6.1. Company market share of key players, 2022
6.2. Competitive Benchmarking
6.3. Market Positioning of Key Vendors
6.4. Geographical Presence Analysis
6.5. Major Strategies Adopted by Key Players
6.5.1. Key Strategies Analysis
6.5.2. Mergers and Acquisitions
6.5.3. Partnerships
6.5.4. Product Launch
6.5.5. Geographical Expansion
6.5.6. Others

7. Impact Analysis of COVID 19 and Russia – Ukraine War on Conjugate Vaccines Market
7.1. Ukraine-Russia War Impact
7.1.1. Uncertainty and Economic Instability
7.1.2. Supply chain disruptions
7.1.3. Regional market shifts
7.1.4. Shift in government priorities
7.2. COVID-19 Impact Analysis
7.2.1. Supply Chain Disruptions
7.2.2. Demand Fluctuations
7.2.3. Shift in Product Mix
7.2.4. Reduced Industrial Activity
7.2.5. Regional Impact Analysis
7.2.5.1. North America
7.2.5.2. Europe
7.2.5.3. Asia Pacific
7.2.5.4. Latin America
7.2.5.5. Middle East and Africa

8. Global Conjugate Vaccines Market, By Target Pathogen
8.1. Global Conjugate Vaccines Market Overview, by Target Pathogen
8.1.1. Global Conjugate Vaccines Market Revenue Share, By Target Pathogen, 2022 Vs 2030 (in %)
8.2. Haemophilus influenzae Type b (Hib) Vaccines
8.2.1. Global Conjugate Vaccines Market, By HAEMOPHILUS INFLUENZAE TYPE B (HIB) VACCINES, By Region, 2017-2030 (US$ Mn)
8.2.2. Market Dynamics for HAEMOPHILUS INFLUENZAE TYPE B (HIB) VACCINES
8.2.2.1. Drivers
8.2.2.2. Restraints
8.2.2.3. Opportunities
8.2.2.4. Trends
8.3. Pneumococcal Vaccines
8.3.1. Global Conjugate Vaccines Market, By PNEUMOCOCCAL VACCINES, By Region, 2017-2030 (US$ Mn)
8.3.2. Market Dynamics for PNEUMOCOCCAL VACCINES
8.3.2.1. Drivers
8.3.2.2. Restraints
8.3.2.3. Opportunities
8.3.2.4. Trends
8.4. Meningococcal Vaccines
8.4.1. Global Conjugate Vaccines Market, By Meningococcal Vaccines, By Region, 2017-2030 (US$ Mn)
8.4.2. Market Dynamics for Meningococcal Vaccines
8.4.2.1. Drivers
8.4.2.2. Restraints
8.4.2.3. Opportunities
8.4.2.4. Trends
8.5. Group B Streptococcus (GBS) Vaccines
8.5.1. Global Conjugate Vaccines Market, By Group B Streptococcus (GBS) Vaccines, By Region, 2017-2030 (US$ Mn)
8.5.2. Market Dynamics for Group B Streptococcus (GBS) Vaccines
8.5.2.1. Drivers
8.5.2.2. Restraints
8.5.2.3. Opportunities
8.5.2.4. Trends
8.6. Salmonella Typhi Vaccines
8.6.1. Global Conjugate Vaccines Market, By Salmonella Typhi Vaccines, By Region, 2017-2030 (US$ Mn)
8.6.2. Market Dynamics for Salmonella Typhi Vaccines
8.6.2.1. Drivers
8.6.2.2. Restraints
8.6.2.3. Opportunities
8.6.2.4. Trends

9. Global Conjugate Vaccines Market, By Age Groups
9.1. Global Conjugate Vaccines Market Overview, By Age Groups
9.1.1. Global Conjugate Vaccines Market Revenue Share, By Age Groups, 2022 Vs 2030 (in %)
9.2. Pediatric Vaccines
9.2.1. Global Conjugate Vaccines Market, By Pediatric Vaccines, By Region, 2017-2030 (US$ Mn)
9.2.2. Market Dynamics for Pediatric Vaccines
9.2.2.1. Drivers
9.2.2.2. Restraints
9.2.2.3. Opportunities
9.2.2.4. Trends
9.3. Adult Vaccines
9.3.1. Global Conjugate Vaccines Market, By Adult Vaccines, By Region, 2017-2030 (US$ Mn)
9.3.2. Market Dynamics for Adult Vaccines
9.3.2.1. Drivers
9.3.2.2. Restraints
9.3.2.3. Opportunities
9.3.2.4. Trends

10. Global Conjugate Vaccines Market, By Carrier Protein
10.1. Global Conjugate Vaccines Market Overview, by Carrier Protein
10.1.1. Global Conjugate Vaccines Market Revenue Share, By Carrier Protein, 2022 Vs 2030 (in %)
10.2. Protein D
10.2.1. Global Conjugate Vaccines Market, By Protein D, By Region, 2017-2030 (US$ Mn)
10.2.2. Market Dynamics for Protein D
10.2.2.1. Drivers
10.2.2.2. Restraints
10.2.2.3. Opportunities
10.2.2.4. Trends
10.3. Tetanus Toxoid
10.3.1. Global Conjugate Vaccines Market, By Tetanus Toxoid, By Region, 2017-2030 (US$ Mn)
10.3.2. Market Dynamics for Tetanus Toxoid
10.3.2.1. Drivers
10.3.2.2. Restraints
10.3.2.3. Opportunities
10.3.2.4. Trends
10.4. Diphtheria Toxoid
10.4.1. Global Conjugate Vaccines Market, By Diphtheria Toxoid, By Region, 2017-2030 (US$ Mn)
10.4.2. Market Dynamics for Diphtheria Toxoid
10.4.2.1. Drivers
10.4.2.2. Restraints
10.4.2.3. Opportunities
10.4.2.4. Trends

11. Global Conjugate Vaccines Market, By Valency
11.1. Global Conjugate Vaccines Market Overview, by Valency
11.1.1. Global Conjugate Vaccines Market Revenue Share, By Valency, 2022 Vs 2030 (in %)
11.2. Monovalent
11.2.1. Global Conjugate Vaccines Market, By Monovalent, By Region, 2017-2030 (US$ Mn)
11.2.2. Market Dynamics for Monovalent
11.2.2.1. Drivers
11.2.2.2. Restraints
11.2.2.3. Opportunities
11.2.2.4. Trends
11.3. Multivalent
11.3.1. Global Conjugate Vaccines Market, By Multivalent, By Region, 2017-2030 (US$ Mn)
11.3.2. Market Dynamics for Multivalent
11.3.2.1. Drivers
11.3.2.2. Restraints
11.3.2.3. Opportunities
11.3.2.4. Trends

12. Global Conjugate Vaccines Market, By Distribution Channel
12.1. Global Conjugate Vaccines Market Overview, by Distribution Channel
12.1.1. Global Conjugate Vaccines Market Revenue Share, By Distribution Channel, 2022 Vs 2030 (in %)
12.2. Public Sector
12.2.1. Global Conjugate Vaccines Market, By Public Sector, By Region, 2017-2030 (US$ Mn)
12.2.2. Market Dynamics for Public Sector
12.2.2.1. Drivers
12.2.2.2. Restraints
12.2.2.3. Opportunities
12.2.2.4. Trends
12.3. Private Sector
12.3.1. Global Conjugate Vaccines Market, By Private Sector, By Region, 2017-2030 (US$ Mn)
12.3.2. Market Dynamics for Private Sector
12.3.2.1. Drivers
12.3.2.2. Restraints
12.3.2.3. Opportunities
12.3.2.4. Trends
13. Global Conjugate Vaccines Market, By Application
13.1. Global Conjugate Vaccines Market Overview, by Application
13.1.1. Global Conjugate Vaccines Market Revenue Share, By Application, 2022 Vs 2030 (in %)
13.2. Preventive Vaccines
13.2.1. Global Conjugate Vaccines Market, By Preventive Vaccines, By Region, 2017-2030 (US$ Mn)
13.2.2. Market Dynamics for Preventive Vaccines
13.2.2.1. Drivers
13.2.2.2. Restraints
13.2.2.3. Opportunities
13.2.2.4. Trends
13.3. Travel Vaccines
13.3.1. Global Conjugate Vaccines Market, By Travel Vaccines, By Region, 2017-2030 (US$ Mn)
13.3.2. Market Dynamics for Travel Vaccines
13.3.2.1. Drivers
13.3.2.2. Restraints
13.3.2.3. Opportunities
13.3.2.4. Trends

14. Global Conjugate Vaccines Market, By Patient Population
14.1. Global Conjugate Vaccines Market Overview, by Patient Population
14.1.1. Global Conjugate Vaccines Market Revenue Share, By Patient Population, 2022 Vs 2030 (in %)
14.2. Pediatric Population
14.2.1. Global Conjugate Vaccines Market, By Pediatric Population, By Region, 2017-2030 (US$ Mn)
14.2.2. Market Dynamics for Pediatric Population
14.2.2.1. Drivers
14.2.2.2. Restraints
14.2.2.3. Opportunities
14.2.2.4. Trends
14.3. High-Risk Populations
14.3.1. Global Conjugate Vaccines Market, By High-Risk Populations, By Region, 2017-2030 (US$ Mn)
14.3.2. Market Dynamics for High-Risk Populations
14.3.2.1. Drivers
14.3.2.2. Restraints
14.3.2.3. Opportunities
14.3.2.4. Trends

15. Global Conjugate Vaccines Market, By Brand
15.1. Global Conjugate Vaccines Market Overview, by Brand
15.1.1. Global Conjugate Vaccines Market Revenue Share, By Brand, 2022 Vs 2030 (in %)
15.2. Brand-Specific Vaccines
15.2.1. Global Conjugate Vaccines Market, By Brand-Specific Vaccines, By Region, 2017-2030 (US$ Mn)
15.2.2. Market Dynamics for Brand-Specific Vaccines
15.2.2.1. Drivers
15.2.2.2. Restraints
15.2.2.3. Opportunities
15.2.2.4. Trends

16. Global Conjugate Vaccines Market, By Region
16.1. Global Conjugate Vaccines Market Overview, by Region
16.1.1. Global Conjugate Vaccines Market, By Region, 2022 vs 2030 (in%)
16.2. Target Pathogen
16.2.1. Global Conjugate Vaccines Market, By Target Pathogen, 2017-2030 (US$ Mn)
16.3. Material
16.3.1. Global Conjugate Vaccines Market, By Age Group, 2017-2030 (US$ Mn)
16.4. Carrier Protein
16.4.1. Global Conjugate Vaccines Market, By Carrier Protein, 2017-2030 (US$ Mn)
16.5. Valency
16.5.1. Global Conjugate Vaccines Market, By Valency, 2017-2030 (US$ Mn)
16.6. Distribution Channel
16.6.1. Global Conjugate Vaccines Market, By Distribution Channel, 2017-2030 (US$ Mn)
16.7. Application
16.7.1. Global Conjugate Vaccines Market, By Application, 2017-2030 (US$ Mn)
16.8. Patient Population
16.8.1. Global Conjugate Vaccines Market, By Patient Population, 2017-2030 (US$ Mn)
16.9. Brand
16.9.1. Global Conjugate Vaccines Market, By Brand, 2017-2030 (US$ Mn)

17. North America Conjugate Vaccines Market Analysis
17.1. Overview
17.1.1. Market Dynamics for North America
17.1.1.1. Drivers
17.1.1.2. Restraints
17.1.1.3. Opportunities
17.1.1.4. Trends
17.2. North America Conjugate Vaccines Market, by Target Pathogen, 2017-2030(US$ Mn)
17.2.1. Overview
17.2.2. SRC Analysis
17.3. North America Conjugate Vaccines Market, By Age Group, 2017-2030(US$ Mn)
17.3.1. Overview
17.3.2. SRC Analysis
17.4. North America Conjugate Vaccines Market, by Carrier Protein, 2017-2030(US$ Mn)
17.4.1. Overview
17.4.2. SRC Analysis
17.5. North America Conjugate Vaccines Market, by Valency, 2017-2030(US$ Mn)
17.5.1. Overview
17.5.2. SRC Analysis
17.6. North America Conjugate Vaccines Market, by Distribution Channel, 2017-2030(US$ Mn)
17.6.1. Overview
17.6.2. SRC Analysis
17.7. North America Conjugate Vaccines Market, by Application, 2017-2030(US$ Mn)
17.7.1. Overview
17.7.2. SRC Analysis
17.8. North America Conjugate Vaccines Market, by Patient Population, 2017-2030(US$ Mn)
17.8.1. Overview
17.8.2. SRC Analysis
17.9. North America Conjugate Vaccines Market, by Brand, 2017-2030(US$ Mn)
17.9.1. Overview
17.9.2. SRC Analysis
17.10. North America Conjugate Vaccines Market, by Country, 2017-2030(US$ Mn)
17.10.1. North America Conjugate Vaccines Market, by Country, 2022 Vs 2030 (in%)
17.10.2. U.S.
17.10.3. Canada
17.10.4. Mexico

18. Europe Conjugate Vaccines Market Analysis
18.1. Overview
18.1.1. Market Dynamics for North America
18.1.1.1. Drivers
18.1.1.2. Restraints
18.1.1.3. Opportunities
18.1.1.4. Trends
18.2. Europe Conjugate Vaccines Market, by Target Pathogen, 2017-2030(US$ Mn)
18.2.1. Overview
18.2.2. SRC Analysis
18.3. Europe Conjugate Vaccines Market, By Age Group, 2017-2030(US$ Mn)
18.3.1. Overview
18.3.2. SRC Analysis
18.4. Europe Conjugate Vaccines Market, by Carrier Protein, 2017-2030(US$ Mn)
18.4.1. Overview
18.4.2. SRC Analysis
18.5. Europe Conjugate Vaccines Market, by Valency, 2017-2030(US$ Mn)
18.5.1. Overview
18.5.2. SRC Analysis
18.6. Europe Conjugate Vaccines Market, by Distribution Channel, 2017-2030(US$ Mn)
18.6.1. Overview
18.6.2. SRC Analysis
18.7. Europe Conjugate Vaccines Market, by Application, 2017-2030(US$ Mn)
18.7.1. Overview
18.7.2. SRC Analysis
18.8. Europe Conjugate Vaccines Market, by Patient Population, 2017-2030(US$ Mn)
18.8.1. Overview
18.8.2. SRC Analysis
18.9. Europe Conjugate Vaccines Market, by Brand, 2017-2030(US$ Mn)
18.9.1. Overview
18.9.2. SRC Analysis
18.10. Europe Conjugate Vaccines Market, by Country, 2017-2030 (US$ Mn)
18.10.1. Europe Conjugate Vaccines Market, by Country, 2022 Vs 2030 (in%)
18.10.2. UK
18.10.3. France
18.10.4. Germany
18.10.5. Italy
18.10.6. Spain
18.10.7. Benelux
18.10.8. Russia
18.10.9. Rest of Europe

19. Asia Pacific Conjugate Vaccines Market Analysis
19.1. Overview
19.1.1. Market Dynamics for North America
19.1.1.1. Drivers
19.1.1.2. Restraints
19.1.1.3. Opportunities
19.1.1.4. Trends
19.2. Asia Pacific Conjugate Vaccines Market, by Target Pathogen, 2017-2030(US$ Mn)
19.2.1. Overview
19.2.2. SRC Analysis
19.3. Asia Pacific Conjugate Vaccines Market, By Age Group, 2017-2030(US$ Mn)
19.3.1. Overview
19.3.2. SRC Analysis
19.4. Asia Pacific Conjugate Vaccines Market, by Carrier Protein, 2017-2030(US$ Mn)
19.4.1. Overview
19.4.2. SRC Analysis
19.5. Asia Pacific Conjugate Vaccines Market, by Valency, 2017-2030(US$ Mn)
19.5.1. Overview
19.5.2. SRC Analysis
19.6. Asia Pacific Conjugate Vaccines Market, by Distribution Channel, 2017-2030(US$ Mn)
19.6.1. Overview
19.6.2. SRC Analysis
19.7. Asia Pacific Conjugate Vaccines Market, by Application, 2017-2030(US$ Mn)
19.7.1. Overview
19.7.2. SRC Analysis
19.8. Asia Pacific Conjugate Vaccines Market, by Patient Population, 2017-2030(US$ Mn)
19.8.1. Overview
19.8.2. SRC Analysis
19.9. Asia Pacific Conjugate Vaccines Market, by Brand, 2017-2030(US$ Mn)
19.9.1. Overview
19.9.2. SRC Analysis
19.10. Asia Pacific Conjugate Vaccines Market, by Country, 2017-2030 (US$ Mn)
19.10.1. Asia Pacific Conjugate Vaccines Market, by Country, 2022 Vs 2030 (in%)
19.10.2. China
19.10.3. Japan
19.10.4. India
19.10.5. South Korea
19.10.6. South East Asia
19.10.7. Rest of Asia Pacific

20. Latin America Conjugate Vaccines Market Analysis
20.1. Overview
20.1.1. Market Dynamics for North America
20.1.1.1. Drivers
20.1.1.2. Restraints
20.1.1.3. Opportunities
20.1.1.4. Trends
20.2. Latin America Conjugate Vaccines Market, by Target Pathogen, 2017-2030(US$ Mn)
20.2.1. Overview
20.2.2. SRC Analysis
20.3. Latin America Conjugate Vaccines Market, By Age Group, 2017-2030(US$ Mn)
20.3.1. Overview
20.3.2. SRC Analysis
20.4. Latin America Conjugate Vaccines Market, by Carrier Protein, 2017-2030(US$ Mn)
20.4.1. Overview
20.4.2. SRC Analysis
20.5. Latin America Conjugate Vaccines Market, by Valency, 2017-2030(US$ Mn)
20.5.1. Overview
20.5.2. SRC Analysis
20.6. Latin America Conjugate Vaccines Market, by Distribution Channel, 2017-2030(US$ Mn)
20.6.1. Overview
20.6.2. SRC Analysis
20.7. Latin America Conjugate Vaccines Market, by Application, 2017-2030(US$ Mn)
20.7.1. Overview
20.7.2. SRC Analysis
20.8. Latin America Conjugate Vaccines Market, by Patient Population, 2017-2030(US$ Mn)
20.8.1. Overview
20.8.2. SRC Analysis
20.9. Latin America Conjugate Vaccines Market, by Brand, 2017-2030(US$ Mn)
20.9.1. Overview
20.9.2. SRC Analysis
20.10. Latin America Conjugate Vaccines Market, by Country, 2017-2030 (US$ Mn)
20.10.1. Latin America Conjugate Vaccines Market, by Country, 2022 Vs 2030 (in%)
20.10.2. Brazil
20.10.3. Argentina
20.10.4. Rest of Latin America

21. Middle East Conjugate Vaccines Market Analysis
21.1. Overview
21.1.1. Market Dynamics for North America
21.1.1.1. Drivers
21.1.1.2. Restraints
21.1.1.3. Opportunities
21.1.1.4. Trends
21.2. Middle East Conjugate Vaccines Market, by Target Pathogen, 2017-2030(US$ Mn)
21.2.1. Overview
21.2.2. SRC Analysis
21.3. Middle East Conjugate Vaccines Market, By Age Group, 2017-2030(US$ Mn)
21.3.1. Overview
21.3.2. SRC Analysis
21.4. Middle East Conjugate Vaccines Market, by Carrier Protein, 2017-2030(US$ Mn)
21.4.1. Overview
21.4.2. SRC Analysis
21.5. Middle East Conjugate Vaccines Market, by Valency, 2017-2030(US$ Mn)
21.5.1. Overview
21.5.2. SRC Analysis
21.6. Middle East Conjugate Vaccines Market, by Distribution Channel, 2017-2030(US$ Mn)
21.6.1. Overview
21.6.2. SRC Analysis
21.7. Middle East Conjugate Vaccines Market, by Application, 2017-2030(US$ Mn)
21.7.1. Overview
21.7.2. SRC Analysis
21.8. Middle East Conjugate Vaccines Market, by Patient Population, 2017-2030(US$ Mn)
21.8.1. Overview
21.8.2. SRC Analysis
21.9. Middle East Conjugate Vaccines Market, by Brand, 2017-2030(US$ Mn)
21.9.1. Overview
21.9.2. SRC Analysis
21.10. Middle East Conjugate Vaccines Market, by Country, 2017-2030 (US$ Mn)
21.10.1. Middle East Conjugate Vaccines Market, by Country, 2022 Vs 2030 (in%)
21.10.2. UAE
21.10.3. Saudi Arabia
21.10.4. Rest of Middle East

22. Africa Conjugate Vaccines Market Analysis
22.1. Overview
22.1.1. Market Dynamics for North America
22.1.1.1. Drivers
22.1.1.2. Restraints
22.1.1.3. Opportunities
22.1.1.4. Trends
22.2. Africa Conjugate Vaccines Market, by Target Pathogen, 2017-2030(US$ Mn)
22.2.1. Overview
22.2.2. SRC Analysis
22.3. Africa Conjugate Vaccines Market, By Age Group, 2017-2030(US$ Mn)
22.3.1. Overview
22.3.2. SRC Analysis
22.4. Africa Conjugate Vaccines Market, by Carrier Protein, 2017-2030(US$ Mn)
22.4.1. Overview
22.4.2. SRC Analysis
22.5. Africa Conjugate Vaccines Market, by Valency, 2017-2030(US$ Mn)
22.5.1. Overview
22.5.2. SRC Analysis
22.6. Africa Conjugate Vaccines Market, by Distribution Channel, 2017-2030(US$ Mn)
22.6.1. Overview
22.6.2. SRC Analysis
22.7. Africa Conjugate Vaccines Market, by Application, 2017-2030(US$ Mn)
22.7.1. Overview
22.7.2. SRC Analysis
22.8. Africa Conjugate Vaccines Market, by Patient Population, 2017-2030(US$ Mn)
22.8.1. Overview
22.8.2. SRC Analysis
22.9. Africa Conjugate Vaccines Market, by Brand, 2017-2030(US$ Mn)
22.9.1. Overview
22.9.2. SRC Analysis
22.10. Africa Conjugate Vaccines Market, by Country, 2017-2030 (US$ Mn)
22.10.1. Middle East Conjugate Vaccines Market, by Country, 2022 Vs 2030 (in%)
22.10.2. South Africa
22.10.3. Egypt
22.10.4. Rest of Africa

23. Company Profiles
23.1. Sanofi S.A
23.1.1. Company Overview
23.1.2. Products/Services Portfolio
23.1.3. Geographical Presence
23.1.4. SWOT Analysis
23.1.5. Financial Summary
23.1.5.1. Market Revenue and Net Profit (2019-2022)
23.1.5.2. Business Segment Revenue Analysis
23.1.5.3. Geographical Revenue Analysis
23.2. Pfizer, Inc.
23.3. Merck & Co., Inc.
23.4. GlaxoSmithKline plc.
23.5. Bharat Biotech, Serum institute of India Pvt. Ltd.
23.6. Biological E. Limited
23.7. Bio-Med
23.8. Bavarian Nordic
23.9. CSL Limited
23.10. Novartis AG
23.11. Vaxcyte
23.12. GSBPL
23.13. Taj Pharmaceuticals Limited
23.14. Bavarian Nordic.

24. Research Methodology
24.1. Research Methodology
24.2. Phase I – Secondary Research
24.3. Phase II – Data Modelling
24.3.1. Company Share Analysis Model
24.3.2. Revenue Based Modelling
24.4. Phase III – Primary Research
24.5. Research Limitations
24.5.1. Assumptions

List of Figures
FIG. 1 Global Conjugate Vaccines Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Conjugate Vaccines Market Segmentation
FIG. 4 Global Conjugate Vaccines Market, by Target Pathogen, 2022 (US$ Mn)
FIG. 5 Global Conjugate Vaccines Market, By Age Group, 2022 (US$ Mn)
FIG. 6 Global Conjugate Vaccines Market, by Carrier Protein, 2022 (US$ Mn)
FIG. 7 Global Conjugate Vaccines Market, by Data Trasnfer Speed, 2022 (US$ Mn)
FIG. 8 Global Conjugate Vaccines Market, by Distribution Channel, 2022 (US$ Mn)
FIG. 9 Global Conjugate Vaccines Market, by Application, 2022 (US$ Mn)
FIG. 10 Global Conjugate Vaccines Market, by Patient Population, 2022 (US$ Mn)
FIG. 11 Global Conjugate Vaccines Market, by Brand, 2022 (US$ Mn)
FIG. 12 Global Conjugate Vaccines Market, by Geography, 2022 (US$ Mn)
FIG. 13 Attractive Investment Proposition, by Target Pathogen, 2022
FIG. 14 Attractive Investment Proposition, By Age Group, 2022
FIG. 15 Attractive Investment Proposition, by Carrier Protein, 2022
FIG. 16 Attractive Investment Proposition, by Valency, 2022
FIG. 17 Attractive Investment Proposition, by Distribution Channel, 2022
FIG. 18 Attractive Investment Proposition, by Application, 2022
FIG. 19 Attractive Investment Proposition, by Patient Population, 2022
FIG. 20 Attractive Investment Proposition, by Brand, 2022
FIG. 21 Attractive Investment Proposition, by Geography, 2022
FIG. 22 Global Market Share Analysis of Key Conjugate Vaccines Market Manufacturers, 2022
FIG. 23 Global Market Positioning of Key Conjugate Vaccines Market Manufacturers, 2022
FIG. 24 Global Conjugate Vaccines Market Value Contribution, By Target Pathogen, 2022 & 2030 (Value %)
FIG. 25 Global Conjugate Vaccines Market, by HAEMOPHILUS INFLUENZAE TYPE B (HIB) VACCINES, Value, 2017-2030 (US$ Mn)
FIG. 26 Global Conjugate Vaccines Market, by PNEUMOCOCCAL VACCINES, Value, 2017-2030 (US$ Mn)
FIG. 27 Global Conjugate Vaccines Market, by Meningococcal Vaccines, Value, 2017-2030 (US$ Mn)
FIG. 28 Global Conjugate Vaccines Market, by Group B Streptococcus (GBS) Vaccines, Value, 2017-2030 (US$ Mn)
FIG. 29 Global Conjugate Vaccines Market, by Salmonella Typhi Vaccines, Value, 2017-2030 (US$ Mn)
FIG. 30 Global Conjugate Vaccines Market Value Contribution, By Age Group, 2022 & 2030 (Value %)
FIG. 31 Global Conjugate Vaccines Market, by Pediatric Vaccines, Value, 2017-2030 (US$ Mn)
FIG. 32 Global Conjugate Vaccines Market, by Adult Vaccines, Value, 2017-2030 (US$ Mn)
FIG. 33 Global Conjugate Vaccines Market Value Contribution, By Carrier Protein, 2022 & 2030 (Value %)
FIG. 34 Global Conjugate Vaccines Market, by Protein D, Value, 2017-2030 (US$ Mn)
FIG. 35 Global Conjugate Vaccines Market, by Tetanus Toxoid, Value, 2017-2030 (US$ Mn)
FIG. 36 Global Conjugate Vaccines Market, by Diphtheria Toxoid, Value, 2017-2030 (US$ Mn)
FIG. 37 Global Conjugate Vaccines Market Value Contribution, By Valency, 2022 & 2030 (Value %)
FIG. 38 Global Conjugate Vaccines Market, by Monovalent, Value, 2017-2030 (US$ Mn)
FIG. 39 Global Conjugate Vaccines Market, by Multivalent, Value, 2017-2030 (US$ Mn)
FIG. 40 Global Conjugate Vaccines Market Value Contribution, By Distribution Channel, 2022 & 2030 (Value %)
FIG. 41 Global Conjugate Vaccines Market, by Public Sector, Value, 2017-2030 (US$ Mn)
FIG. 42 Global Conjugate Vaccines Market, by Private Sector, Value, 2017-2030 (US$ Mn)
FIG. 43 Global Conjugate Vaccines Market Value Contribution, By Application, 2022 & 2030 (Value %)
FIG. 44 Global Conjugate Vaccines Market, by Preventive Vaccines, Value, 2017-2030 (US$ Mn)
FIG. 45 Global Conjugate Vaccines Market, by Travel Vaccines, Value, 2017-2030 (US$ Mn)
FIG. 46 Global Conjugate Vaccines Market Value Contribution, By Patient Population, 2022 & 2030 (Value %)
FIG. 47 Global Conjugate Vaccines Market, by Pediatric Population, Value, 2017-2030 (US$ Mn)
FIG. 48 Global Conjugate Vaccines Market, by High-Risk Populations, Value, 2017-2030 (US$ Mn)
FIG. 49 Global Conjugate Vaccines Market Value Contribution, By Brand, 2022 & 2030 (Value %)
FIG. 50 Global Conjugate Vaccines Market, by Brand-Specific Vaccines, Value, 2017-2030 (US$ Mn)
FIG. 51 North America Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 52 U.S. Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 53 Canada Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 54 Mexico Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 55 Europe Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 56 Germany Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 57 France Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 58 U.K. Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 59 Italy Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 60 Spain Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 61 Benelux Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 62 Russia Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 63 Rest of Europe Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 64 Asia Pacific Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 65 China Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 66 Japan Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 67 India Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 68 South Korea Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 69 South-East Asia Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 70 Rest of Asia Pacific Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 71 Latin America Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 72 Brazil Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 73 Argentina Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 74 Rest of Latin America Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 75 Middle East Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 76 UAE Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 77 Saudi Arabia Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 78 Rest of Middle East Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 79 Africa Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 80 South Africa Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 81 Egypt Conjugate Vaccines Market, 2017-2030 (US$ Mn)
FIG. 82 Rest of Africa Conjugate Vaccines Market, 2017-2030 (US$ Mn)

List of Tables
TABLE 1 Market Snapshot: Global Conjugate Vaccines Market
TABLE 2 Global Conjugate Vaccines Market: Market Drivers Impact Analysis
TABLE 3 Global Conjugate Vaccines Market: Market Restraints Impact Analysis
TABLE 4 Global Conjugate Vaccines Market, by Competitive Benchmarking, 2022
TABLE 5 Global Conjugate Vaccines Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Conjugate Vaccines Market, by Key Strategies Analysis, 2022
TABLE 7 Global Conjugate Vaccines Market, by HAEMOPHILUS INFLUENZAE TYPE B (HIB) VACCINES, By Region, 2017-2022 (US$ Mn)
TABLE 8 Global Conjugate Vaccines Market, by HAEMOPHILUS INFLUENZAE TYPE B (HIB) VACCINES, By Region, 2023-2030 (US$ Mn)
TABLE 9 Global Conjugate Vaccines Market, by PNEUMOCOCCAL VACCINES, By Region, 2017-2022 (US$ Mn)
TABLE 10 Global Conjugate Vaccines Market, by PNEUMOCOCCAL VACCINES, By Region, 2023-2030 (US$ Mn)
TABLE 11 Global Conjugate Vaccines Market, by Meningococcal Vaccines, By Region, 2017-2022 (US$ Mn)
TABLE 12 Global Conjugate Vaccines Market, by Meningococcal Vaccines, By Region, 2023-2030 (US$ Mn)
TABLE 13 Global Conjugate Vaccines Market, by Group B Streptococcus (GBS) Vaccines, By Region, 2017-2022 (US$ Mn)
TABLE 14 Global Conjugate Vaccines Market, by Group B Streptococcus (GBS) Vaccines, By Region, 2023-2030 (US$ Mn)
TABLE 15 Global Conjugate Vaccines Market, by Salmonella Typhi Vaccines, By Region, 2017-2022 (US$ Mn)
TABLE 16 Global Conjugate Vaccines Market, by Salmonella Typhi Vaccines, By Region, 2023-2030 (US$ Mn)
TABLE 17 Global Conjugate Vaccines Market, by Pediatric Vaccines, By Region, 2017-2022 (US$ Mn)
TABLE 18 Global Conjugate Vaccines Market, by Pediatric Vaccines, By Region, 2023-2030 (US$ Mn)
TABLE 19 Global Conjugate Vaccines Market, by Adult Vaccines, By Region, 2017-2022 (US$ Mn)
TABLE 20 Global Conjugate Vaccines Market, by Adult Vaccines, By Region, 2023-2030 (US$ Mn)
TABLE 21 Global Conjugate Vaccines Market, by Protein D, By Region, 2017-2022 (US$ Mn)
TABLE 22 Global Conjugate Vaccines Market, by Protein D, By Region, 2023-2030 (US$ Mn)
TABLE 23 Global Conjugate Vaccines Market, by Tetanus Toxoid, By Region, 2017-2022 (US$ Mn)
TABLE 24 Global Conjugate Vaccines Market, by Tetanus Toxoid, By Region, 2023-2030 (US$ Mn)
TABLE 25 Global Conjugate Vaccines Market, by Diphtheria Toxoid, By Region, 2017-2022 (US$ Mn)
TABLE 26 Global Conjugate Vaccines Market, by Diphtheria Toxoid, By Region, 2023-2030 (US$ Mn)
TABLE 27 Global Conjugate Vaccines Market, by Monovalent, By Region, 2017-2022 (US$ Mn)
TABLE 28 Global Conjugate Vaccines Market, by Monovalent, By Region, 2023-2030 (US$ Mn)
TABLE 29 Global Conjugate Vaccines Market, by Multivalent, By Region, 2017-2022 (US$ Mn)
TABLE 30 Global Conjugate Vaccines Market, by Multivalent, By Region, 2023-2030 (US$ Mn)
TABLE 31 Global Conjugate Vaccines Market, by Public Sector, By Region, 2017-2022 (US$ Mn)
TABLE 32 Global Conjugate Vaccines Market, by Public Sector, By Region, 2023-2030 (US$ Mn)
TABLE 33 Global Conjugate Vaccines Market, by Private Sector, By Region, 2017-2022 (US$ Mn)
TABLE 34 Global Conjugate Vaccines Market, by Private Sector, By Region, 2023-2030 (US$ Mn)
TABLE 35 Global Conjugate Vaccines Market, by Preventive Vaccines, By Region, 2017-2022 (US$ Mn)
TABLE 36 Global Conjugate Vaccines Market, by Preventive Vaccines, By Region, 2023-2030 (US$ Mn)
TABLE 37 Global Conjugate Vaccines Market, by Travel Vaccines, By Region, 2017-2022 (US$ Mn)
TABLE 38 Global Conjugate Vaccines Market, by Travel Vaccines, By Region, 2023-2030 (US$ Mn)
TABLE 39 Global Conjugate Vaccines Market, by High-Risk Populations-speed Interface, By Region, 2017-2022 (US$ Mn)
TABLE 40 Global Conjugate Vaccines Market, by High-Risk Populations-speed Interface, By Region, 2023-2030 (US$ Mn)
TABLE 41 Global Conjugate Vaccines Market, by High- Brand-Specific Vaccines, By Region, 2017-2022 (US$ Mn)
TABLE 42 Global Conjugate Vaccines Market, by Brand-Specific Vaccines, By Region, 2023-2030 (US$ Mn)
TABLE 43 Global Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 44 Global Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 45 Global Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 46 Global Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 47 Global Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 48 Global Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 49 Global Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 50 Global Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 51 Global Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 52 Global Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 53 Global Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 54 Global Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 55 Global Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 56 Global Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 57 Global Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 58 Global Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 59 Global Conjugate Vaccines Market, by Region, 2017-2022 (US$ Mn)
TABLE 60 Global Conjugate Vaccines Market, by Region, 2023-2030 (US$ Mn)
TABLE 61 North America Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 62 North America Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 63 North America Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 64 North America Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 65 North America Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 66 North America Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 67 North America Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 68 North America Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 69 North America Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 70 North America Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 71 North America Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 72 North America Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 73 North America Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 74 North America Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 75 North America Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 76 North America Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 77 North America Conjugate Vaccines Market, by Country, 2017-2022 (US$ Mn)
TABLE 78 North America Conjugate Vaccines Market, by Country, 2023-2030 (US$ Mn)
TABLE 79 United States Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 80 United States Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 81 United States Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 82 United States Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 83 United States Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 84 United States Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 85 United States Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 86 United States Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 87 United States Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 88 United States Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 89 United States Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 90 United States Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 91 United States Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 92 United States Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 93 United States Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 94 United States Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 95 Canada Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 96 Canada Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 97 Canada Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 98 Canada Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 99 Canada Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 100 Canada Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 101 Canada Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 102 Canada Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 103 Canada Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 104 Canada Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 105 Canada Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 106 Canada Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 107 Canada Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 108 Canada Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 109 Canada Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 110 Canada Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 111 Mexico Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 112 Mexico Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 113 Mexico Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 114 Mexico Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 115 Mexico Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 116 Mexico Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 117 Mexico Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 118 Mexico Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 119 Mexico Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 120 Mexico Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 121 Mexico Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 122 Mexico Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 123 Mexico Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 124 Mexico Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 125 Mexico Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 126 Mexico Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 127 Europe Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 128 Europe Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 129 Europe Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 130 Europe Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 131 Europe Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 132 Europe Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 133 Europe Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 134 Europe Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 135 Europe Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 136 Europe Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 137 Europe Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 138 Europe Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 139 Europe Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 140 Europe Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 141 Europe Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 142 Europe Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 143 Europe Conjugate Vaccines Market, by Country, 2017-2022 (US$ Mn)
TABLE 144 Europe Conjugate Vaccines Market, by Country, 2023-2030 (US$ Mn)
TABLE 145 Germany Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 146 Germany Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 147 Germany Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 148 Germany Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 149 Germany Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 150 Germany Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 151 Germany Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 152 Germany Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 153 Germany Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 154 Germany Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 155 Germany Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 156 Germany Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 157 Germany Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 158 Germany Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 159 Germany Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 160 Germany Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 161 France Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 162 France Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 163 France Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 164 France Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 165 France Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 166 France Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 167 France Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 168 France Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 169 France Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 170 France Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 171 France Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 172 France Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 173 France Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 174 France Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 175 France Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 176 France Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 177 United Kingdom Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 178 United Kingdom Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 179 United Kingdom Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 180 United Kingdom Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 181 United Kingdom Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 182 United Kingdom Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 183 United Kingdom Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 184 United Kingdom Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 185 United Kingdom Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 186 United Kingdom Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 187 United Kingdom Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 188 United Kingdom Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 189 United Kingdom Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 190 United Kingdom Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 191 United Kingdom Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 192 United Kingdom Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 193 Italy Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 194 Italy Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 195 Italy Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 196 Italy Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 197 Italy Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 198 Italy Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 199 Italy Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 200 Italy Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 201 Italy Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 202 Italy Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 203 Italy Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 204 Italy Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 205 Italy Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 206 Italy Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 207 Italy Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 208 Italy Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 209 Spain Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 210 Spain Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 211 Spain Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 212 Spain Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 213 Spain Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 214 Spain Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 215 Spain Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 216 Spain Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 217 Spain Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 218 Spain Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 219 Spain Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 220 Spain Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 221 Spain Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 222 Spain Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 223 Spain Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 224 Spain Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 225 Benelux Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 226 Benelux Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 227 Benelux Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 228 Benelux Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 229 Benelux Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 230 Benelux Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 231 Benelux Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 232 Benelux Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 233 Benelux Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 234 Benelux Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 235 Benelux Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 236 Benelux Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 237 Benelux Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 238 Benelux Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 239 Benelux Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 240 Benelux Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 241 Russia Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 242 Russia Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 243 Russia Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 244 Russia Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 245 Russia Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 246 Russia Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 247 Russia Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 248 Russia Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 249 Russia Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 250 Russia Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 251 Russia Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 252 Russia Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 253 Russia Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 254 Russia Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 255 Russia Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 256 Russia Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 257 Rest of Europe Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 258 Rest of Europe Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 259 Rest of Europe Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 260 Rest of Europe Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 261 Rest of Europe Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 262 Rest of Europe Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 263 Rest of Europe Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 264 Rest of Europe Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 265 Rest of Europe Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 266 Rest of Europe Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 267 Rest of Europe Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 268 Rest of Europe Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 269 Rest of Europe Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 270 Rest of Europe Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 271 Rest of Europe Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 272 Rest of Europe Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 273 Asia Pacific Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 274 Asia Pacific Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 275 Asia Pacific Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 276 Asia Pacific Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 277 Asia Pacific Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 278 Asia Pacific Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 279 Asia Pacific Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 280 Asia Pacific Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 281 Asia Pacific Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 282 Asia Pacific Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 283 Asia Pacific Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 284 Asia Pacific Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 285 Asia Pacific Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 286 Asia Pacific Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 287 Asia Pacific Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 288 Asia Pacific Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 289 China Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 290 China Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 291 China Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 292 China Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 293 China Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 294 China Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 295 China Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 296 China Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 297 China Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 298 China Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 299 China Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 300 China Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 301 China Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 302 China Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 303 China Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 304 China Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 305 Japan Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 306 Japan Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 307 Japan Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 308 Japan Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 309 Japan Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 310 Japan Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 311 Japan Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 312 Japan Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 313 Japan Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 314 Japan Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 315 Japan Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 316 Japan Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 317 Japan Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 318 Japan Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 319 Japan Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 320 Japan Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 321 India Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 322 India Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 323 India Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 324 India Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 325 India Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 326 India Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 327 India Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 328 India Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 329 India Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 330 India Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 331 India Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 332 India Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 333 India Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 334 India Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 335 India Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 336 India Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 337 South Korea Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 338 South Korea Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 339 South Korea Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 340 South Korea Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 341 South Korea Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 342 South Korea Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 343 South Korea Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 344 South Korea Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 345 South Korea Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 346 South Korea Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 347 South Korea Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 348 South Korea Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 349 South Korea Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 350 South Korea Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 351 South Korea Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 352 South Korea Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 353 South-East Asia Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 354 South-East Asia Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 355 South-East Asia Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 356 South-East Asia Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 357 South-East Asia Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 358 South-East Asia Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 359 South-East Asia Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 360 South-East Asia Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 361 South-East Asia Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 362 South-East Asia Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 363 South-East Asia Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 364 South-East Asia Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 365 South-East Asia Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 366 South-East Asia Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 367 South-East Asia Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 368 South-East Asia Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 369 Rest of Asia Pacific Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 370 Rest of Asia Pacific Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 371 Rest of Asia Pacific Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 372 Rest of Asia Pacific Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 373 Rest of Asia Pacific Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 374 Rest of Asia Pacific Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 375 Rest of Asia Pacific Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 376 Rest of Asia Pacific Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 377 Rest of Asia Pacific Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 378 Rest of Asia Pacific Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 379 Rest of Asia Pacific Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 380 Rest of Asia Pacific Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 381 Rest of Asia Pacific Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 382 Rest of Asia Pacific Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 383 Rest of Asia Pacific Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 384 Rest of Asia Pacific Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 385 Latin America Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 386 Latin America Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 387 Latin America Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 388 Latin America Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 389 Latin America Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 390 Latin America Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 391 Latin America Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 392 Latin America Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 393 Latin America Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 394 Latin America Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 395 Latin America Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 396 Latin America Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 397 Latin America Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 398 Latin America Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 399 Latin America Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 400 Latin America Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 401 Brazil Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 402 Brazil Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 403 Brazil Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 404 Brazil Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 405 Brazil Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 406 Brazil Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 407 Brazil Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 408 Brazil Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 409 Brazil Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 410 Brazil Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 411 Brazil Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 412 Brazil Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 413 Brazil Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 414 Brazil Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 415 Brazil Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 416 Brazil Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 417 Argentina Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 418 Argentina Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 419 Argentina Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 420 Argentina Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 421 Argentina Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 422 Argentina Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 423 Argentina Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 424 Argentina Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 425 Argentina Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 426 Argentina Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 427 Argentina Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 428 Argentina Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 429 Argentina Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 430 Argentina Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 431 Argentina Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 432 Argentina Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 433 Rest of Latin America Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 434 Rest of Latin America Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 435 Rest of Latin America Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 436 Rest of Latin America Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 437 Rest of Latin America Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 438 Rest of Latin America Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 439 Rest of Latin America Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 440 Rest of Latin America Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 441 Rest of Latin America Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 442 Rest of Latin America Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 443 Rest of Latin America Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 444 Rest of Latin America Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 445 Rest of Latin America Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 446 Rest of Latin America Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 447 Rest of Latin America Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 448 Rest of Latin America Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 449 Middle East Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 450 Middle East Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 451 Middle East Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 452 Middle East Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 453 Middle East Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 454 Middle East Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 455 Middle East Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 456 Middle East Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 457 Middle East Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 458 Middle East Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 459 Middle East Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 460 Middle East Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 461 Middle East Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 462 Middle East Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 463 Middle East Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 464 Middle East Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 465 UAE Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 466 UAE Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 467 UAE Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 468 UAE Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 469 UAE Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 470 UAE Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 471 UAE Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 472 UAE Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 473 UAE Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 474 UAE Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 475 UAE Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 476 UAE Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 477 UAE Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 478 UAE Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 479 UAE Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 480 UAE Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 481 Saudi Arabia Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 482 Saudi Arabia Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 483 Saudi Arabia Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 484 Saudi Arabia Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 485 Saudi Arabia Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 486 Saudi Arabia Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 487 Saudi Arabia Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 488 Saudi Arabia Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 489 Saudi Arabia Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 490 Saudi Arabia Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 491 Saudi Arabia Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 492 Saudi Arabia Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 493 Saudi Arabia Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 494 Saudi Arabia Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 495 Saudi Arabia Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 496 Saudi Arabia Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 497 Rest of Middle East Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 498 Rest of Middle East Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 499 Rest of Middle East Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 500 Rest of Middle East Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 501 Rest of Middle East Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 502 Rest of Middle East Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 503 Rest of Middle East Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 504 Rest of Middle East Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 505 Rest of Middle East Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 506 Rest of Middle East Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 507 Rest of Middle East Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 508 Rest of Middle East Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 509 Rest of Middle East Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 510 Rest of Middle East Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 511 Rest of Middle East Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 512 Rest of Middle East Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 513 Africa Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 514 Africa Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 515 Africa Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 516 Africa Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 517 Africa Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 518 Africa Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 519 Africa Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 520 Africa Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 521 Africa Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 522 Africa Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 523 Africa Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 524 Africa Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 525 Africa Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 526 Africa Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 527 Africa Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 528 Africa Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 529 South Africa Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 530 South Africa Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 531 South Africa Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 532 South Africa Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 533 South Africa Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 534 South Africa Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 535 South Africa Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 536 South Africa Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 537 South Africa Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 538 South Africa Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 539 South Africa Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 540 South Africa Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 541 South Africa Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 542 South Africa Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 543 South Africa Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 544 South Africa Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 545 Egypt Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 546 Egypt Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 547 Egypt Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 548 Egypt Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 549 Egypt Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 550 Egypt Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 551 Egypt Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 552 Egypt Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 553 Egypt Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 554 Egypt Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 555 Egypt Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 556 Egypt Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 557 Egypt Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 558 Egypt Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 559 Egypt Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 560 Egypt Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)
TABLE 561 Rest of Africa Conjugate Vaccines Market, by Target Pathogen, 2017-2022 (US$ Mn)
TABLE 562 Rest of Africa Conjugate Vaccines Market, by Target Pathogen, 2023-2030 (US$ Mn)
TABLE 563 Rest of Africa Conjugate Vaccines Market, By Age Group, 2017-2022 (US$ Mn)
TABLE 564 Rest of Africa Conjugate Vaccines Market, By Age Group, 2023-2030 (US$ Mn)
TABLE 565 Rest of Africa Conjugate Vaccines Market, by Carrier Protein, 2017-2022 (US$ Mn)
TABLE 566 Rest of Africa Conjugate Vaccines Market, by Carrier Protein, 2023-2030 (US$ Mn)
TABLE 567 Rest of Africa Conjugate Vaccines Market, by Valency, By Region, 2017-2022 (US$ Mn)
TABLE 568 Rest of Africa Conjugate Vaccines Market, by Valency, By Region, 2023-2030 (US$ Mn)
TABLE 569 Rest of Africa Conjugate Vaccines Market, by Distribution Channel, 2017-2022 (US$ Mn)
TABLE 570 Rest of Africa Conjugate Vaccines Market, by Distribution Channel, 2023-2030 (US$ Mn)
TABLE 571 Rest of Africa Conjugate Vaccines Market, by Application, 2017-2022 (US$ Mn)
TABLE 572 Rest of Africa Conjugate Vaccines Market, by Application, 2023-2030 (US$ Mn)
TABLE 573 Rest of Africa Conjugate Vaccines Market, by Patient Population, 2017-2022 (US$ Mn)
TABLE 574 Rest of Africa Conjugate Vaccines Market, by Patient Population, 2023-2030 (US$ Mn)
TABLE 575 Rest of Africa Conjugate Vaccines Market, by Brand, 2017-2022 (US$ Mn)
TABLE 576 Rest of Africa Conjugate Vaccines Market, by Brand, 2023-2030 (US$ Mn)

Frequently asked questions

What is the current Carrier Protein of the worldwide Conjugate Vaccines Market?

In 2022, the global Conjugate Vaccines Market is expected to be worth USD 18154.5million.

What is the predicted growth rate of the Conjugate Vaccines Market between 2023 and 2030?

The Conjugate Vaccines Market is estimated to increase at a CAGR of 10.00% between 2023 and 2030, reaching USD 38915.7 Million in 2030.

Which segment has the most market share in terms of valency?

In 2022, Multivalent Conjugate Vaccines have the largest market share.

Which patient population segment governs the market demand for Conjugate Vaccines?

The Pediatric Population drives market demand

Which age group segment is predicted to grow at the highest rate over the forecast period?

The adult market will also accelerate, but children will have the highest CAGR.

Which region is driving the Conjugate Vaccines industry forward?

North America would account for 35% of the total market in 2022

Who are the major players in the global Conjugate Vaccines Market?

The top players include Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech

What are the major market drivers of the Conjugate Vaccines industry?

Raising awareness of the need of bacterial infection vaccine Advances in vaccination technology that result in better efficacy and safety Growing government initiatives and immunization programs to avoid infectious diseases are the primary market drivers.

What are the major market restraints of the Conjugate Vaccines industry?

High costs involved with the research and production of conjugate vaccines, stringent regulatory criteria for vaccine approval and market entrance, and limited accessibility and affordability of vaccinations in particular locations are market restraints.

What are the major market opportunities of the Conjugate Vaccines industry?

The key market opportunity is the expansion of the market in emerging economies with growing healthcare infrastructure, the development of conjugate vaccines for new target diseases and age groups, and collaboration and partnerships among pharmaceutical companies to enhance research and development efforts.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –